Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.51 |
| ▸ | FLT1 | P17948 | 5/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.36 |
| ▸ | FLT4 | P35916 | 4/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.36 |
| ▸ | LCK | P06239 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24393356 | 0.59 | KDR (0.38) | KDREGFR | |
| SCHEMBL23939418 | 0.59 | KDR (0.37) | KDREGFR | |
| SCHEMBL24392406 | 0.59 | KDR (0.37) | KDREGFR | |
| SCHEMBL14883217 | 0.58 | L3MBTL1 (0.47) | CYP1A2 | |
| SCHEMBL4386662 | 0.57 | CASP3 (0.68) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL16583512 | 0.56 | L3MBTL1 (0.44) | EGFR | |
| SCHEMBL24392514 | 0.56 | KDR (0.35) | KDREGFR | |
| SCHEMBL20928945 | 0.56 | L3MBTL1 (0.45) | KDRFGFR1 | |
| SCHEMBL4815952 | 0.56 | KDR (0.42) | KDRFGFR1 | |
| SCHEMBL12537638 | 0.55 | EGFR (0.52) | KDRFLT1FLT4ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1543009-A4 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | BHIDE RAJEEV S | 2005-10-20 | — | — | US | disclosed |
| US-6951859-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1543009-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004013145-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | FGFR1, FLT1, FGFR2 | KDR 7/4885FGFR1 1/4885FLT1 2/4885 |
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | FGFR1, FLT1, FGFR2 | KDR 7/4885FGFR1 1/4885FLT1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.